These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 16918408)

  • 1. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting.
    Meyer A; Auernheimer J; Modlinger A; Kessler H
    Curr Pharm Des; 2006; 12(22):2723-47. PubMed ID: 16918408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrins in drug targeting-RGD templates in toxins.
    Lu X; Lu D; Scully MF; Kakkar VV
    Curr Pharm Des; 2006; 12(22):2749-69. PubMed ID: 16918409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer.
    Sani S; Messe M; Fuchs Q; Pierrevelcin M; Laquerriere P; Entz-Werle N; Reita D; Etienne-Selloum N; Bruban V; Choulier L; Martin S; Dontenwill M
    Chembiochem; 2021 Apr; 22(7):1151-1160. PubMed ID: 33140906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in biomedical applications of RGD-based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review.
    Alipour M; Baneshi M; Hosseinkhani S; Mahmoudi R; Jabari Arabzadeh A; Akrami M; Mehrzad J; Bardania H
    J Biomed Mater Res A; 2020 Apr; 108(4):839-850. PubMed ID: 31854488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligands for mapping alphavbeta3-integrin expression in vivo.
    Schottelius M; Laufer B; Kessler H; Wester HJ
    Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGD and other recognition sequences for integrins.
    Ruoslahti E
    Annu Rev Cell Dev Biol; 1996; 12():697-715. PubMed ID: 8970741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles.
    Arosio D; Casagrande C; Manzoni L
    Curr Med Chem; 2012; 19(19):3128-51. PubMed ID: 22612699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis.
    Dresner-Pollak R; Rosenblatt M
    J Cell Biochem; 1994 Nov; 56(3):323-30. PubMed ID: 7876325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.
    Zheng Y; Leftheris K
    J Med Chem; 2020 Jun; 63(11):5675-5696. PubMed ID: 31999923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating angiogenesis with integrin-targeted nanomedicines.
    Duro-Castano A; Gallon E; Decker C; Vicent MJ
    Adv Drug Deliv Rev; 2017 Sep; 119():101-119. PubMed ID: 28502767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RGD-based Therapy: Principles of Selectivity.
    Rubtsov MA; Syrkina MS; Aliev G
    Curr Pharm Des; 2016; 22(7):932-52. PubMed ID: 26648463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
    Sheldrake HM; Patterson LH
    J Med Chem; 2014 Aug; 57(15):6301-15. PubMed ID: 24568695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
    Arosio D; Manzoni L; Corno C; Perego P
    Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets.
    Sun CC; Qu XJ; Gao ZH
    Am J Ther; 2016; 23(1):e198-207. PubMed ID: 24621642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting by surface-modified protein microspheres.
    Toublan FJ; Boppart S; Suslick KS
    J Am Chem Soc; 2006 Mar; 128(11):3472-3. PubMed ID: 16536492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of beta-amino acid-containing integrin antagonists.
    Scarborough RM
    Curr Med Chem; 1999 Oct; 6(10):971-81. PubMed ID: 10519908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular imaging of avb3 expression in cancer patients.
    Gaertner FC; Schwaiger M; Beer AJ
    Q J Nucl Med Mol Imaging; 2010 Jun; ():. PubMed ID: 20559198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C; Dormond O; Mariotti A
    Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates.
    Shukla R; Thomas TP; Peters J; Kotlyar A; Myc A; Baker JR
    Chem Commun (Camb); 2005 Dec; (46):5739-41. PubMed ID: 16307130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand.
    Hall ER; Bibby LI; Slack RJ
    Biochem Pharmacol; 2016 Oct; 117():88-96. PubMed ID: 27501918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.